We are recruiting children between the ages of 2 and 17 years old with plaque psoriasis to participate in an investigational study. The purpose of the study is to evaluate the safety and tolerability of tapinarof cream, 1% when applied once daily on areas of the skin with plaque psoriasis.
The study consists of applying tapinarof cream, 1% once daily over a 12-week period. This is an open-label study which means that there is no placebo and participants are guaranteed to receive the study treatment. The total duration of the primary treatment phase will be approximately 17 weeks which include up to 4 weeks for screening, a 12-week treatment phase, and a follow up visit during week 13. There is an option for participants to continue use of the treatment for an additional 40-weeks.  You will have a total of 8 in-person clinic visits, including your initial screening visit and 1 follow-up visit once you have finished receiving the study treatment. Visits take approximately 1 to3 hours each, except for the screening, week 4, week 8, and week 12 visits which may take up to 5 hours. Blood samples will be collected from all participants at each visit.
You will be provided with all study-related medication, examinations and medical care at no cost to you. Compensation for time and travel may be available.
See if you are eligible for the study!